Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Begna on Recent Advancements in MPNs

Kebede H. Begna, MD
Published: Tuesday, May 16, 2017



Kebede H. Begna, MD, assistant professor of Medicine, Mayo Clinic, discusses some of the recent advancements in the field of myeloproliferative neoplasms (MPNs).

The advancements have mainly been in terms of diagnosis, Begna explains. Over the last several years, molecular abnormalities have been identified that are thought to be targeted with therapies, including JAK2V6171 and CALR as described in patients with myelofibrosis and essential thrombocytopenia.

Also recently, next-generation sequencing is helping physicians to define more molecular abnormalities, especially regarding prognosis of patients with myelofibrosis. This is a way to help physicians advise patients what direction to go in terms of their treatment. 
 


Kebede H. Begna, MD, assistant professor of Medicine, Mayo Clinic, discusses some of the recent advancements in the field of myeloproliferative neoplasms (MPNs).

The advancements have mainly been in terms of diagnosis, Begna explains. Over the last several years, molecular abnormalities have been identified that are thought to be targeted with therapies, including JAK2V6171 and CALR as described in patients with myelofibrosis and essential thrombocytopenia.

Also recently, next-generation sequencing is helping physicians to define more molecular abnormalities, especially regarding prognosis of patients with myelofibrosis. This is a way to help physicians advise patients what direction to go in terms of their treatment. 
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x